{"prompt": "['Protocol RS-001', 'Confidential', '8.6.1 Dose Modification for Participants on inducers of CYP3A4 and/or PgP', 'Co-administration with strong inducers of CYP3A4 or P-glycoprotein (PgP) should be avoided', 'when possible. Co-administration with moderate CYP3A4 or PgP inducers should be used with', 'caution. That said, there may be participants on CNS agents known to be inducers of CYP3A4', '(barbiturates, carbamazepine, oxcarbazepine, phenobarbital, phenytoin, valproic acid,', 'benzodiazepines) that need to be continued on their medication regimen. No dosage adjustment', 'of ABI-009 will be made for these participants; they will be dosed at the current stage of dose', 'finding based on Table 3.', '8.6.2 Dose Modification for Participants on inhibitors of CYP3A4 and/or PgP', 'Co-administration with strong inhibitors of CYP3A4 or P-glycoprotein (PgP) should also be', 'avoided when possible. Co-administration with moderate CYP3A4 inhibitors (e.g.,', 'erythromycin, fluconazole) or PgP inhibitors should be used with caution. If the participant', 'requires co-administration of moderate CYP3A4 inhibitors or PgP inhibitors, ABI-009 dose will', 'be reduced to the next lower dose according to Table 3. (Additional dose reductions to every', 'other day may be required to manage toxicities. If the inhibitor is discontinued the ABI-009 dose', 'should be returned to the dose used prior to initiation of the moderate CYP3A4/PgP inhibitor', 'after a washout period of 2 to 3 days. Seville orange, star fruit, grapefruit and their juices affect', 'P450 and PgP activity. Concomitant use should be avoided.', '8.6.3 Missed Study Drug Doses', 'Missed doses of study drug should be recorded. Our intention is to tightly adhere to the weekly', 'schedule of medication administration.', '8.7', 'Management of known adverse events associated with mTOR inhibitors', '8.7.1 Management of Hepatitis reactivation/flare', 'Monitoring and prophylactic treatment for hepatitis B reactivation should occur based on the', 'institutional standard for pediatric participants and in consultation with a pediatric', 'gastrointestinal specialist and/or pediatric infectious disease.', '8.7.2 Management of stomatitis/oral mucositis/mouth ulcers', 'Stomatitis/oral mucositis/mouth ulcers due to mTOR inhibitors should be treated using local', 'supportive care. Please note that investigators in earlier trials have described the oral toxicities', 'associated with mTOR inhibitors as mouth ulcers, rather than mucositis or stomatitis. If your', 'examination reveals mouth ulcers rather than a more general inflammation of the mouth, please', 'classify the adverse event as such. Please follow the paradigm below for treatment of', 'stomatitis/oral mucositis/mouth ulcers:', '1. For mild toxicity (Grade 1), conservative measures such as non-alcoholic mouth wash or salt', 'water (0.9%) mouthwash several times a day until resolution is recommended', '2. For more severe toxicity (Grade 2 in which case participants have pain but are able to maintain', 'adequate oral alimentation, or Grade 3 in which case participants cannot maintain adequate oral', 'alimentation), the suggested treatments are topical analgesic mouth treatments (i.e., local', 'anesthetics such as benzocaine, butyl aminobenzoate, tetracaine hydrochloride, menthol, or', 'Version 2', 'Version Date: October 31, 2018', 'Page 43 of 72']['Protocol RS-001', 'Confidential', 'phenol) with or without topical corticosteroids, such as triamcinolone oral paste 0.1% (Kenalog', 'in Orabase\u00ae).', '3. Agents containing hydrogen peroxide, iodine, and thyme derivatives may tend to worsen', 'mouth ulcers. It is preferable to avoid these agents.', '4. Antifungal agents must be avoided unless a fungal infection is diagnosed. In particular,', 'systemic imidazole antifungal agents (ketoconazole, fluconazole, itraconazole, etc.) should be', 'avoided in all participants due to their strong inhibition of mTOR inhibitor metabolism, thereby', 'leading to higher m TOR inhibitor exposures. Therefore, topical antifungal agents are preferred if', 'an infection is diagnosed. Similarly, antiviral agents such as acyclovir should be avoided unless a', 'viral infection is diagnosed.', 'Note: Stomatitis/oral mucositis should be appropriately graded using the functional grading', 'given on the NCI-CTCAE for adverse events, v5.', '8.7.3 Management of hyperlipidemia and hyperglycemia', 'Treatment of hyperlipidemia should take into account the pre-treatment status and dietary habits.', 'Blood tests to monitor hyperlipidemia must be taken in the fasting state. Hyperlipidemia and', 'hypertriglyceridemia should be treated according to local best clinical practice. Participants', 'should be monitored clinically and through serum chemistry for the development of', 'rhabdomyolysis and other adverse events as required in the product label/data sheets for', 'HMGCoA reductase inhibitors. Hyperglycemia has been reported in clinical trials. Monitoring of', 'fasting serum glucose is recommended prior to the start of m TOR inhibitor dosing and', 'periodically thereafter. Optimal glycemic control should be achieved before starting study drug', 'dosing.', '8.7.4 Management of non-infectious pneumonitis', 'Non-infectious pneumonitis is a class effect of rapamycin derivatives. Cases of non-infectious', 'pneumonitis (including interstitial lung disease) have also been described in participants taking', 'mTOR inhibitors. Some of these have been severe and on rare occasions, a fatal outcome was', 'observed.', 'A diagnosis of non-infectious pneumonitis should be considered in participants presenting with', 'nonspecific respiratory signs and symptoms such as hypoxia, pleural effusion, cough or dyspnea,', 'and in whom infectious, neoplastic and other non-medicinal causes have been excluded by', 'means of appropriate investigations. Participants should be advised to report promptly any new', 'or worsening respiratory symptoms. Participants who develop radiological changes suggestive of', 'non-infectious pneumonitis and have few or no symptoms may continue m TOR inhibitor dosing', 'without dose alteration. If symptoms are moderate (Grade 2), consideration should be given to', 'interruption of dosing until symptoms improve. The use of corticosteroids may be indicated.', 'mTOR inhibitor may be reintroduced once at a reduced dose until recovery to Grade 1 or better.', 'For cases where symptoms of non-infectious pneumonitis are severe (Grade 3), mTOR inhibitor', 'dosing should be discontinued and the use of corticosteroids may be indicated until clinical', 'symptoms resolve. Dosing with mTOR inhibitors may be re-initiated at a reduced dose', 'depending on individual clinical circumstances.', 'Table 5. Pneumonitis Management and ABI-009 Dosing', 'Version 2', 'Version Date: October 31, 2018', 'Page 44 of 72']\n\n###\n\n", "completion": "END"}